The TIFA study is an ongoing multicenter, randomized Phase II clinical trial designed to assess the efficacy of SGLT2i canagliflozin in combination with standard-of-care treatment alpelisib plus fulvestrant in preventing PI3K inhibitor-associated hyperglycemia in patients with metastatic, PIK3CA-mutant, HR+HER2- breast cancer (NCT05090358). This evidence concerns the gene ERBB2 and breast carcinoma.